164 related articles for article (PubMed ID: 36165233)
1. The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.
Patergnani S; Giattino A; Bianchi N; Giorgi C; Pinton P; Aguiari G
Biol Cell; 2023 Jan; 115(1):e2200037. PubMed ID: 36165233
[TBL] [Abstract][Full Text] [Related]
2. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
3. Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion.
Wilk EJ; Howton TC; Fisher JL; Oza VH; Brownlee RT; McPherson KC; Cleary HL; Yoder BK; George JF; Mrug M; Lasseigne BN
Mol Med; 2023 May; 29(1):67. PubMed ID: 37217845
[TBL] [Abstract][Full Text] [Related]
4. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.
Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G
Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
de Stephanis L; Mangolini A; Servello M; Harris PC; Dell'Atti L; Pinton P; Aguiari G
J Cell Physiol; 2018 Sep; 233(9):6911-6924. PubMed ID: 29323708
[TBL] [Abstract][Full Text] [Related]
7. TRPP2 dysfunction decreases ATP-evoked calcium, induces cell aggregation and stimulates proliferation in T lymphocytes.
Magistroni R; Mangolini A; Guzzo S; Testa F; Rapanà MR; Mignani R; Russo G; di Virgilio F; Aguiari G
BMC Nephrol; 2019 Sep; 20(1):355. PubMed ID: 31514750
[TBL] [Abstract][Full Text] [Related]
8. Multidrug therapy for polycystic kidney disease: a review and perspective.
Aguiari G; Catizone L; Del Senno L
Am J Nephrol; 2013; 37(2):175-82. PubMed ID: 23428809
[TBL] [Abstract][Full Text] [Related]
9. Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.
Mekahli D; Decuypere JP; Sammels E; Welkenhuyzen K; Schoeber J; Audrezet MP; Corvelyn A; Dechênes G; Ong AC; Wilmer MJ; van den Heuvel L; Bultynck G; Parys JB; Missiaen L; Levtchenko E; De Smedt H
Pflugers Arch; 2014 Aug; 466(8):1591-604. PubMed ID: 24193408
[TBL] [Abstract][Full Text] [Related]
10. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model.
Zhu P; Sieben CJ; Xu X; Harris PC; Lin X
Hum Mol Genet; 2017 Jan; 26(1):158-172. PubMed ID: 28007903
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic advances in ADPKD: the future awaits.
Capuano I; Buonanno P; Riccio E; Amicone M; Pisani A
J Nephrol; 2022 Mar; 35(2):397-415. PubMed ID: 34009558
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease.
Bastos AP; Onuchic LF
Braz J Med Biol Res; 2011 Jul; 44(7):606-17. PubMed ID: 21625823
[TBL] [Abstract][Full Text] [Related]
13. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
14. Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations.
Freedman BS; Lam AQ; Sundsbak JL; Iatrino R; Su X; Koon SJ; Wu M; Daheron L; Harris PC; Zhou J; Bonventre JV
J Am Soc Nephrol; 2013 Oct; 24(10):1571-86. PubMed ID: 24009235
[TBL] [Abstract][Full Text] [Related]
15. Role of apoptosis in the development of autosomal dominant polycystic kidney disease (ADPKD).
Peintner L; Borner C
Cell Tissue Res; 2017 Jul; 369(1):27-39. PubMed ID: 28560694
[TBL] [Abstract][Full Text] [Related]
16. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
[TBL] [Abstract][Full Text] [Related]
17. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
18. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca
Yanda MK; Liu Q; Cebotaru V; Guggino WB; Cebotaru L
J Biol Chem; 2017 Oct; 292(43):17897-17908. PubMed ID: 28887310
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus.
Stayner C; Shields J; Slobbe L; Shillingford JM; Weimbs T; Eccles MR
Nephrology (Carlton); 2012 Nov; 17(8):739-47. PubMed ID: 22725947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
